We aim to capture the body’s own nanovesicles transport system to enable effective, safe, and tissue-targeted delivery of next-generation drugs.
Focus is given to the areas with the highest breakthrough potential due to practical feasibility, medical need, and likelihood of success:
- Precision-targeted delivery of drugs to tumors and metastatic sites, avoiding adverse reactions due to drug exposure in healthy tissue.
- Effective delivery of drugs across the blood-brain barrier, opening up the chemical space for treatment of neurodegenerative and brain diseases to gene therapy or antibodies.
- Achieving bioavailability of new drug modalities with high application potential but poor permeability and/or rapid clearance, such as nucleic acids, complex heterobifunctional ligands, or large ribonucleoprotein complexes (gene editing therapeutics), and the use of food-derived EVs for oral drug delivery.
Our aim is to deliver first candidate applications as well as proof-of-principle for the technology, while our long-term vision is to develop an nanovesicle drug delivery platform with even broader application potential.
